Amarin Corp. PLC (AMRN) Trading Up 0.7%
Amarin Corp. PLC (NASDAQ:AMRN) was up 0.7% during trading on Wednesday . The company traded as high as $2.89 and last traded at $2.81, with a volume of 2,853,181 shares trading hands. The stock had previously closed at $2.79.
A number of equities research analysts have recently commented on AMRN shares. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of Amarin Corp. PLC in a report on Monday, May 9th. Jefferies Group started coverage on shares of Amarin Corp. PLC in a report on Thursday, May 12th. They issued a “buy” rating and a $3.50 target price for the company. Finally, Zacks Investment Research cut shares of Amarin Corp. PLC from a “hold” rating to a “sell” rating in a report on Tuesday, May 17th.
The stock has a 50-day moving average price of $2.83 and a 200 day moving average price of $2.04. The stock’s market cap is $516.74 million.
Amarin Corp. PLC (NASDAQ:AMRN) last released its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.13) by $0.06. The firm had revenue of $32.82 million for the quarter, compared to analyst estimates of $29.97 million. Amarin Corp. PLC’s revenue for the quarter was up 85.4% on a year-over-year basis. During the same period in the previous year, the business posted ($0.15) earnings per share. Equities research analysts predict that Amarin Corp. PLC will post ($0.46) EPS for the current year.
Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company’s lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.